Skip to main content

Table 2 Combinations of CD39/CD73/A2AR inhibitors and other cancer therapies under investigation in clinical trials (https://clinicaltrials.gov/)

From: CD39/CD73/A2AR pathway and cancer immunotherapy

Combination

Company

Mechanism

phase

NCT number

Combination SRF617 with pembrolizumab gemcitabine albuminbound paclitaxel

Surface Oncology

Merck Sharp & Dohme LLC

CD39 antagonist with chemotherapy

Phase I

NCT04336098

Combination TTX-030 with immunotherapy and/or chemotherapy

Trishula Therapeutics, Inc.

AbbVie

Anti-CD39 antibody with immunotherapy

Phase I

NCT04306900

Combination SRF617 with AB928 (Etrumadenent) and AB122 (zimberelimab)

Surface Oncology

Arcus Biosciences, Inc

Anti-CD39 antibody with A2AR and A2BR antagonist

Phase I

NCT05177770

Combination IPH5301 with chemotherapy and trastuzumab

Institut Paoli-Calmettes

Innate Pharma

Anti-CD73 antibody with chemotherapy

Phase I

NCT05143970

Combination AK119 with AK104

Akeso

Anti-CD73 antibody with chemotherapy

Phase I

NCT04572152

Combination IBI325 with sintilimab

Innovent Biologics (Suzhou) Co. Ltd.

Anti-CD73 antibody with chemotherapy

Phase I

NCT05119998

Combination oleclumab with gemcitabine, nab-paclitaxel, durvalumab

M.D. Anderson Cancer Center

Anti-CD73 antibody with chemotherapy

PhaseII

NCT04940286

Combination dalutrafusp (GS-1423) with mFOLFOX6 regimen

Gilead Sciences

Anti-CD73-TGFβ-Trap antibody with chemotherapy

Phase I

NCT03954704

Combination LY3475070 with pembrolizumab

Eli Lilly and Company

Merck Sharp & Dohme LLC

CD73 antagonist with immunotherapy

Phase I

NCT04148937

Combination BMS-986179 with nivolumab (BMS-936558)

Bristol-Myers Squibb

CD73 antagonist with immunotherapy

Phase II

NCT02754141

Combination INCA00186 with INCB106385 and/or retifanlimab

Incyte Corporation

CD73 antagonist with immunotherapy

Phase I

NCT04989387

Combination TJ004309 with atezolizumab

I-Mab Biopharma US Limited

I-Mab Biopharma Co. Ltd.

Anti-CD73 antibody with immunotherapy

Phase II

NCT05001347

Combination JAB-BX102 with pembrolizumab

Jacobio Pharmaceuticals Co., Ltd.

Anti-CD73 antibody with immunotherapy

Phase II

NCT05174585

Combination PT199 with an anti-PD-1 monoclonal antibody

Phanes Therapeutics

Anti-CD73 antibody with immunotherapy

Phase I

NCT05431270

Combination NZV930 with PDR001

Novartis Pharmaceuticals

Novartis

Anti-CD73 antibody with immunotherapy

Phase I

NCT03549000

Combination Sym024 with Sym021

Symphogen A/S

Anti-CD73 antibody with immunotherapy

Phase I

NCT04672434

Combination oleclumab (MEDI9447) with AZD4635

MedImmune LLC

Anti-CD73 antibody with A2AR antagonist

Phase Ib/II

NCT03381274

Combination CPI-006 with ciforadenant or pembrolizumab

Corvus Pharmaceuticals, Inc

Anti-CD73 antibody with A2AR antagonist

Phase I

NCT03454451

Combination inupadenant (EOS100850) with Chemotherapy

iTeos Belgium SA

iTeos Therapeutics

A2AR antagonist with chemotherapy

Phase II

NCT05403385

Combination INCB106385 with immunotherapy

Incyte Corporation

A2AR antagonist with immunotherapy

Phase I

NCT04580485

Combination NZV930 with PDR001 and /or NIR178

Novartis Pharmaceuticals

Novartis

A2AR antagonist with immunotherapy

Phase I

NCT03549000

Combination lpilimumab, nivolumab with ciforadenant (CPI-444)

M.D. Anderson Cancer Center

A2AR antagonist with immunotherapy

phase I/II

NCT05501054

Combination NIR178 with PDR001

Novartis Pharmaceuticals

Novartis

A2AR antagonist with immunotherapy

Phase II

NCT03207867

Combination taminadenant with PDR001

Palobiofarma SL

Novartis

H. Lee Moffitt Cancer Center and Research Institute

A2AR antagonist with immunotherapy

Phase I

NCT02403193

Combination DFF332, spartalizumab with taminadenant

Novartis Pharmaceuticals

Novartis

A2AR antagonist with immunotherapy

Phase I

NCT04895748

Combination AZD4635 with durvalumab or oleclumab (MEDI9447)

AstraZeneca

A2AR antagonist with anti-CD73 antibody

Phase II

NCT04089553

  1. Combing CD39/CD73/A2AR with other therapies is an attractive therapeutic strategy for cancer treatment. Targeting CD39/CD73/A2AR with blocking antibodies or small-molecule inhibitors in combination with other therapies such as immune checkpoint blockade and chemotherapy is a rational strategy to enhance therapeutic benefit